Attorney for Transvaginal Mesh Patients Asks FDA to Make Regulatory Changes

Attorney for Transvaginal Mesh Patients Asks FDA to Make Regulatory Changes In a letter dated August 22, 2011, Phoenix attorney Van O’Steen asked the Federal Food and Drug Administration (FDA) to make regulatory changes affecting the use of transvaginal surgical mesh implants for treatment of pelvic organ prolapse (POP) and Stress Urinary Incontinence (SUI). O’Steen’s law firm represents a number of women throughout the United States who have experienced serious complications following surgery to implant vaginal mesh devices. Phoenix, Arizona (PRWEB) August 22, 2011 In a letter dated Au
Contributor
About
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations